Congenital Cytomegalovirus Testing Outcomes From the ValEAR Trial.
congenital cytomegalovirus
dried blood spot testing
hearing-targeted cytomegalovirus testing
pediatric hearing loss
universal cytomegalovirus testing
Journal
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
ISSN: 1097-6817
Titre abrégé: Otolaryngol Head Neck Surg
Pays: England
ID NLM: 8508176
Informations de publication
Date de publication:
28 Feb 2024
28 Feb 2024
Historique:
revised:
13
11
2023
received:
19
06
2023
accepted:
02
12
2023
medline:
28
2
2024
pubmed:
28
2
2024
entrez:
28
2
2024
Statut:
aheadofprint
Résumé
To determine the positivity rate of congenital cytomegalovirus (cCMV) testing among universal, hearing-targeted CMV testing (HT-cCMV) and delayed targeted dried blood spot (DBS) testing newborn screening programs, and to examine the characteristics of successful HT-cCMV testing programs. Prospective survey of birth hospitals performing early CMV testing. Multiple institutions. Birth hospitals participating in the National Institutes of Health ValEAR clinical trial were surveyed to determine the rates of cCMV positivity associated with 3 different testing approaches: universal testing, HT-cCMV, and DBS testing. A mixed methods model was created to determine associations between successful HT-cCMV screening and specific screening protocols. Eighty-two birth hospitals were surveyed from February 2019 to December 2021. Seven thousand six hundred seventy infants underwent universal screening, 9017 infants HT-cCMV and 535 infants delayed DBS testing. The rates of cCMV positivity were 0.5%, 1.5%, and 7.3%, respectively. The positivity rate for universal CMV screening was less during the COVID-19 pandemic than that reported prior to the pandemic. There were no statistically significant drops in positivity for any approach during the pandemic. For HT-cCMV testing, unique order sets and rigorous posttesting protocols were associated with successful screening programs. Rates of cCMV positivity differed among the 3 approaches. The rates are comparable to cohort studies reported in the literature. Universal CMV prevalence decreased during the pandemic but not significantly. Institutions with specific order set for CMV testing where the primary care physician orders the test and the nurse facilitates the testing process exhibited higher rates of HT-cCMV testing.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 American Academy of Otolaryngology-Head and Neck Surgery Foundation.
Références
Park AH, Duval M, McVicar S, Bale JF, Hohler N, Carey JC. A diagnostic paradigm including cytomegalovirus testing for idiopathic pediatric sensorineural hearing loss. Laryngoscope. 2014;124(11):2624-2629.
Fowler KB, Stagno S, Pass RF. Maternal age and congenital cytomegalovirus infection: screening of two diverse newborn populations, 1980-1990. J Infect Dis. 1993;168(3):552-556.
Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol. 2007;17(4):253-276.
Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol. 2007;17(5):355-363.
Fowler KB, Boppana SB. Congenital cytomegalovirus (CMV) infection and hearing deficit. J Clin Virol. 2006;35(2):226-231.
Grosse SD, Ross DS, Dollard SC. Congenital cytomegalovirus (CMV) infection as a cause of permanent bilateral hearing loss: a quantitative assessment. J Clin Virol. 2008;41(2):57-62.
Iwasaki S, Yamashita M, Maeda M, Misawa K, Mineta H. Audiological outcome of infants with congenital cytomegalovirus infection in a prospective study. Audiol Neurootol. 2007;12(1):31-36.
Plosa EJ, Esbenshade JC, Fuller MP, Weitkamp JH. Cytomegalovirus infection. Pediatr Rev. 2012;33(4):156-163.
Bale JF, Miner L, Petheram SJ. Congenital cytomegalovirus infection. Curr Treat Options Neurol. 2002;4(3):225-230.
Cheeran MCJ, Lokensgard JR, Schleiss MR. Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention. Clin Microbiol Rev. 2009;22(1):99-126.
Demmler GJ. Congenital cytomegalovirus infection and disease. Adv Pediatr Infect Dis. 1996;11:135-162.
Fowler KB, McCollister FP, Dahle AJ, Boppana S, Britt WJ, Pass RF. Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection. J Pediatr. 1997;130(4):624-630.
Di Nardo W, Cattani P, Scorpecci A, et al. Cytomegalovirus DNA retrieval in the inner ear fluids of a congenitally deaf child one month after primary infection: a case report. Laryngoscope. 2011;121(4):828-830.
Luck S, Sharland M. Postnatal Cytomegalovirus: innocent bystander or hidden problem. Arch Dis Child Fetal Neonatal Ed. 2008;94:F58-F64.
Pesch MH, Danziger P, Ross LF, Antommaria AHM. An ethical analysis of newborn congenital cytomegalovirus screening. Pediatrics. 2022;149(6):e2021055368.
Dollard SC, Dreon M, Hernandez-Alvarado N, et al. Sensitivity of dried blood spot testing for detection of congenital cytomegalovirus infection. JAMA Pediatr. 2021;175(3):e205441.
Fowler KB, McCollister FP, Sabo DL, et al. A targeted approach for congenital cytomegalovirus screening within newborn hearing screening. Pediatrics. 2017;139(2):20162128.
Barbi M, Binda S, Primache V, et al. Cytomegalovirus DNA detection in Guthrie cards: a powerful tool for diagnosing congenital infection. J Clin Virol. 2000;17(3):159-165.
Ssentongo P, Hehnly C, Birungi P, et al. Congenital cytomegalovirus infection burden and epidemiologic risk factors in countries with universal screening: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(8):e2120736.
Forli F, Lazzerini F, Canelli R, et al. Extended-hearing targeted screening for congenital cytomegalovirus infection. Minerva Pediatr (Torino). 2021. In press. doi:10.23736/S2724-5276.21.06287-X
Ari-Even Roth D, Lubin D, Kuint J, et al. Contribution of targeted saliva screening for congenital CMV-related hearing loss in newborns who fail hearing screening. Arch Dis Child Fetal Neonatal Ed. 2017;102(6):F519-F524.
Williams EJ, Kadambari S, Berrington JE, et al. Feasibility and acceptability of targeted screening for congenital CMV-related hearing loss. Arch Dis Child Fetal Neonatal Ed. 2014;99(3):F230-F236.
Beswick R, David M, Higashi H, et al. Integration of congenital cytomegalovirus screening within a newborn hearing screening programme. J Paediatr Child Health. 2019;55(11):1381-1388.
Diener ML, Zick CD, McVicar SB, Boettger J, Park AH. Outcomes from a hearing-targeted cytomegalovirus screening program. Pediatrics. 2017;139(2):e20160789.
Raynor E, Holmes C, Crowson M, Peskoe S, Planey A, Lantos PM. Loss to follow up of failed hearing screen and missed opportunities to detect congenital cytomegalovirus are better identified with the implementation of a new electronic health record system protocol. Int J Pediatr Otorhinolaryngol. 2021;148:110818.
Ronner EA, Glovsky CK, Herrmann BS, Woythaler MA, Pasternack MS, Cohen MS. Congenital cytomegalovirus targeted screening implementation and outcomes: a retrospective chart review. Otolaryngol Head Neck Surg. 2022;167(1):178-182.
Pellegrinelli L, Galli C, Primache V, et al. Diagnosis of congenital CMV infection via DBS samples testing and neonatal hearing screening: an observational study in Italy. BMC Infect Dis. 2019;19(1):652.
Meyer L, Sharon B, Huang TC, et al. Analysis of archived newborn dried blood spots (DBS) identifies congenital cytomegalovirus as a major cause of unexplained pediatric sensorineural hearing loss. Am J Otolaryngol. 2017;38(5):565-570.
Lee ER, Chan DK. Implications of dried blood spot testing for congenital CMV on management of children with hearing loss: a preliminary report. Int J Pediatr Otorhinolaryngol. 2019;119:10-14.
Misono S, Sie KCY, Weiss NS, et al. Congenital cytomegalovirus infection in pediatric hearing loss. Arch Otolaryngol Head Neck Surg. 2011;137(1):47-53.
Vancor E, Shapiro ED, Loyal J. Results of a targeted screening program for congenital cytomegalovirus infection in infants who fail newborn hearing screening. J Pediatric Infect Dis Soc. 2019;8(1):55-59.
Fourgeaud J, Boithias C, Walter-Nicolet E, et al. Performance of targeted congenital cytomegalovirus screening in newborns failing universal hearing screening: a multicenter study. Pediatr Infect Dis J. 2022;41(6):478-481.
Webb E, Gillespie AN, Poulakis Z, et al. Feasibility and acceptability of targeted salivary cytomegalovirus screening through universal newborn hearing screening. J Paediatr Child Health. 2022;58(2):288-294.
Yamamoto AY, Anastasio ART, Massuda ET, et al. Contribution of congenital cytomegalovirus infection to permanent hearing loss in a highly seropositive population: the Brazilian cytomegalovirus hearing and maternal secondary infection study. Clin Infect Dis. 2020;70(7):1379-1384.
Hildebrandt RJ, Sever JL, Margileth AM, Callagan DA. Cytomegalovirus in the normal pregnant woman. Am J Obstet Gynecol. 1967;98(8):1125-1128.
Hanshaw JB, Steinfeld HJ, White CJ. Fluorescent-antibody test for cytomegalovirus macroglobulin. N Engl J Med. 1968;279(11):566-570.
Birnbaum G, Lynch JI, Margileth AM, Lonergan WM, Sever JL. Cytomegalovirus infections in newborn infants. J Pediatr. 1969;75(5):789-795.
Starr JG, Bart Jr. RD, Gold E. Inapparent congenital cytomegalovirus infection. Clinical and epidemiologic characteristics in early infancy. N Engl J Med. 1970;282(19):1075-1078.
Melish ME. Congenital cytomegalovirus infection. Developmental progress of infants detected by routine screening. Am J Dis Child. 1973;126(2):190-194.
Embil JA, Macdonald JM, Scott KE. Survey of a neonatal population for the prevalence of cytomegalovirus. Scand J Infect Dis. 1975;7(3):165-167.
Andersen HK, Brostrøm K, Hansen KB, et al. A prospective study on the incidence and significance of congenital cytomegalovirus infection. Acta Paediatr (Stockholm). 1979;68(3):329-336.
Larke RPB, Wheatley E, Saigal S, Chernesky MA. Congenital cytomegalovirus infection in an urban Canadian community. J Infect Dis. 1980;142(5):647-653.
Montgomery JR, Mason Jr. EO, Williamson AP, Desmond MM, South MA. Prospective study of congenital cytomegalovirus infection. South Med J. 1980;73(5):590-593.
Peckham CS, Chin KS, Coleman JC, Henderson K, Hurley R, Preece PM. Cytomegalovirus infection in pregnancy: preliminary findings from a prospective study. Lancet. 1983;321(8338):1352-1355.
Kamada M, Komori A, Chiba S, Nakao T. A prospective study of congenital cytomegalovirus infection in Japan. Scand J Infect Dis. 1983;15(3):227-232.
Ahlfors K, Ivarsson SA, Harris S, et al. Congenital cytomegalovirus infection and disease in Sweden and the relative importance of primary and secondary maternal infections. Preliminary findings from a prospective study. Scand J Infect Dis. 1984;16(2):129-137.
Stagno S. Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. JAMA. 1986;256(14):1904-1908.
Yow MD, Williamson DW, Leeds LJ, et al. Epidemiologic characteristics of cytomegalovirus infection in mothers and their infants. Am J Obstet Gynecol. 1988;158(5):1189-1195.
Griffiths PD, Baboonian C, Rutter D, Peckham C. Congenital and maternal cytomegalovirus infections in a London population. Br J Obstet Gynaecol. 1991;98(2):135-140.
Sohn YM, Park KI, Lee C, Han DG, Lee WY. Congenital cytomegalovirus infection in Korean population with very high prevalence of maternal immunity. J Korean Med Sci. 1992;7(1):47-51.
Tsai CH, Tsai FJ, Shih YT, Wu SF, Liu SC, Tseng YH. Detection of congenital cytomegalovirus infection in Chinese newborn infants using polymerase chain reaction. Acta Paediatr (Stockholm). 1996;85(10):1241-1243.
Luchsinger V, Suárez M, Schultz R, et al. Incidence of congenital cytomegalovirus infection in newborn infants of different socioeconomic strata. Rev Med Chil. 1996;124(4):403-408.
Barbi M, Binda S, Primache V, Clerici D. Congenital cytomegalovirus infection in a northern Italian region. NEOCMV Group. Eur J Epidemiol. 1998;14(8):791-796.
Boppana SB, Fowler KB, Britt WJ, Stagno S, Pass RF. Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus. Pediatrics. 1999;104(1 pt 1):55-60.
Halwachs-Baumann G, Genser B. Screening and diagnosis of congenital cytomegalovirus infection: a 5-y study. Scand J Infect Dis. 2000;32(2):137-142.
Schlesinger Y. Urine polymerase chain reaction as a screening tool for the detection of congenital cytomegalovirus infection. Arch Dis Child Fetal Neonatal Ed. 2003;88(5):371F-374F.
Numazaki K, Fujikawa T. Chronological changes of incidence and prognosis of children with asymptomatic congenital cytomegalovirus infection in Sapporo, Japan. BMC Infect Dis. 2004;4:22.
Gaytant MA, Galama JMD, Semmekrot BA, et al. The incidence of congenital cytomegalovirus infections in The Netherlands. J Med Virol. 2005;76(1):71-75.
Yamagishi Y, Miyagawa H, Wada K, et al. CMV DNA detection in dried blood spots for diagnosing congenital CMV infection in Japan. J Med Virol. 2006;78(7):923-925.
Barbi M, Binda S, Caroppo S, et al. Multicity Italian study of congenital cytomegalovirus infection. Pediatr Infect Dis J. 2006;25(2):156-159.
Estripeaut D, Moreno Y, Ahumada Ruiz S, Martínez A, Racine JD, Sáez-Llorens X. Seroprevalencia de la infección por citomegalovirus en puérperas y su impacto neonatal. Anales de Pediatría. 2007;66(2):135-139.
Foulon I, Naessens A, Foulon W, Casteels A, Gordts F. A 10-year prospective study of sensorineural hearing loss in children with congenital cytomegalovirus infection. J Pediatr. 2008;153(1):84-88.
Engman ML, Malm G, Engström L, et al. Congenital CMV infection: prevalence in newborns and the impact on hearing deficit. Scand J Infect Dis. 2008;40(11-12):935-942.
Endo T, Goto K, Ito K, et al. Detection of congenital cytomegalovirus infection using umbilical cord blood samples in a screening survey. J Med Virol. 2009;81(10):1773-1776.
Boppana SB. Dried blood spot real-time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection. JAMA. 2010;303(14):1375-1382.
Koyano S, Inoue N, Oka A, et al. Screening for congenital cytomegalovirus infection using newborn urine samples collected on filter paper: feasibility and outcomes from a multicentre study. BMJ Open. 2011;1(1):e000118.
de Vries JJC, Korver AMH, Verkerk PH, et al. Congenital cytomegalovirus infection in the Netherlands: birth prevalence and risk factors. J Med Virol. 2011;83(10):1777-1782.
Boppana SB, Ross SA, Shimamura M, et al. Saliva polymerase-chain-reaction assay for cytomegalovirus screening in newborns. N Engl J Med. 2011;364(22):2111-2118.
Paradiž KR, Seme K, Puklavec E, Paro-Panjan D, Poljak M. Prevalence of congenital cytomegalovirus infection in Slovenia: a study on 2,841 newborns. J Med Virol. 2012;84(1):109-115.
Barkai G, Barzilai A, Mendelson E, Tepperberg-Oikawa M, Roth DA, Kuint J. Newborn screening for congenital cytomegalovirus using real-time polymerase chain reaction in umbilical cord blood. Isr Med Assoc J. 2013;15(6):279-283.
Barkai G, Ari-Even Roth D, Barzilai A, et al. Universal neonatal cytomegalovirus screening using saliva-report of clinical experience. J Clin Virol. 2014;60(4):361-366.
Waters A, Jennings K, Fitzpatrick E, et al. Incidence of congenital cytomegalovirus infection in Ireland: implications for screening and diagnosis. J Clin Virol. 2014;59(3):156-160.
Pinninti SG, Ross SA, Shimamura M, et al. Comparison of saliva PCR assay versus rapid culture for detection of congenital cytomegalovirus infection. Pediatr Infect Dis J. 2015;34(5):536-537.
Yamaguchi A, Oh-Ishi T, Arai T, et al. Screening for seemingly healthy newborns with congenital cytomegalovirus infection by quantitative real-time polymerase chain reaction using newborn urine: an observational study. BMJ Open. 2017;7(1):e013810.
Leruez-Ville M, Magny JF, Couderc S, et al. Risk factors for congenital cytomegalovirus infection following primary and nonprimary maternal infection. Clin Infect Dis. 2017;65(3):398-404.
Barlinn R, Dudman SG, Trogstad L, et al. Maternal and congenital cytomegalovirus infections in a population-based pregnancy cohort study. APMIS. 2018;126(12):899-906.
Puhakka L, Lappalainen M, Lönnqvist T, et al. The Burden of congenital cytomegalovirus infection: a prospective cohort study of 20 000 infants in Finland. J Pediatric Infect Dis Soc. 2019;8(3):205-212.
Uchida A, Tanimura K, Morizane M, et al. Clinical factors associated with congenital cytomegalovirus infection: a cohort study of pregnant women and newborns. Clin Infect Dis. 2020;71(11):2833-2839.
Yamada H, Tanimura K, Fukushima S, et al. A cohort study of the universal neonatal urine screening for congenital cytomegalovirus infection. J Infect Chemother. 2020;26(8):790-794.
Stehel EK, Shoup AG, Owen KE, et al. Newborn hearing screening and detection of congenital cytomegalovirus infection. Pediatrics. 2008;121(5):970-975.
Choi KY, Schimmenti LA, Jurek AM, et al. Detection of cytomegalovirus DNA in dried blood spots of Minnesota infants who do not pass newborn hearing screening. Pediatr Infect Dis J. 2009;28(12):1095-1098.
Ross SA, Ahmed A, Palmer AL, et al. Newborn dried blood spot polymerase chain reaction to identify infants with congenital cytomegalovirus-associated sensorineural hearing loss. J Pediatr. 2017;184:57-61.e1.
Jenks CM, DeSell M, Walsh J. Delays in infant hearing detection and intervention during the COVID-19 pandemic: commentary. Otolaryngol Head Neck Surg. 2022;166(4):603-604.
Fernandez C, Chasqueira MJ, Marques A, et al. Lower prevalence of congenital cytomegalovirus infection in Portugal: possible impact of COVID-19 lockdown? Eur J Pediatr. 2022;181(3):1259-1262.
Schleiss MR, Rosendahl S, McCann M, Dollard SC, Lanzieri TM. Assessment of congenital cytomegalovirus prevalence among newborns in Minnesota during the COVID-19 pandemic. JAMA Netwp Open. 2022;5(9):e2230020.